Markets are soaring as votes continue to roll in for the yet-to-be-decided presidential election. We’ll dig into what we know so far, and give you the latest calls from crucial swing states. Plus, our market experts break down what this monster rally should signal to investors. 

It’s the eve of the election, and a lot is at stake for investors. From tech regulation, to taxes and energy policy, there’s a ton riding on the outcome. We’ll follow everything you need to know – including the record money pouring into campaigns, and all the possible outcomes for stocks in the coming days. Plus, our own Meg Tirrell explains why Regeneron’s promising COVID-19 antibody treatment would be in short supply if the FDA approved it today.